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1. Introduction 
Breast cancer is a genetically and clinically heterogeneous disease. Based on this heterogeneit, breast 
cancer can be classified according to the presence and expression of three molecular markers: 
estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 
(HER2). These classification schemes have evolved over many decades into a useful tool for 
treatment choices and patients prognosis. 
Triple-negative breast cancer (TNBC) is an aggressive histological subtype characterized by a lack 
of ER, PR, and HER2 receptors. TNBC  accounts for 10-17% of all breast carcinomas (Haffty et al, 
2006; Penault-Llorca and Viale, 2012), it is often correlated with shorter disease-free and overall 
survival compared with those of women affected by non-TNBC (Dent et al., 2007; Liedtke et al., 
2008). 
Extensive genomic studies of breast tumors have identified distinct groups with differences in 
survival and response to therapy, establishing five major breast cancer intrinsic subtypes:  
- luminal A, characterized by the presence of ER and PgR but with low or absent HER2 expression, 
- luminal B, triple positive for ER, PgR and HER2;  
- HER2-enriched,  characterized by the absence of ER and PgR but HER2 positive; 
- basal-like, triple negative for  ER-/PgR-/HER2 and showing Basal Markers.   
- claudin-low, characterized by low to absent expression of luminal differentiation markers, high 
enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer 
stem cell like features. 
After the advent of genomic analysis and the subtyping of breast cancers according to gene expression 
profiles many have used the terms TNBC and “basal-like” as synonymous. However, the spectrum 
of TNBC is heterogeneous: While 75% to 80% of TNBC cases correlate with the “basal” or “claudin-
low” subtypes, about 9% are HER2-positive, and 11% have some hormone receptor gene expression 
(5% luminal A; 6% luminal B) (Figure 1). However, clinically decisions are based upon the 
immunohistochemical profile of a tumor is obtained, which, in the case of TNBC, is marked by the 
absence of the three commonly tested receptors. 
 
 
 
 
Figure 1. Breast cancer subtypes. Triple-negative breast cancer (TNBC)  accounts for 10% to 20%, HER2 positive for 
about 15% and ER/PgR positive for 65% of all breast cancers. While 75% to 80% of TNBC cases correlate with the 
“basal” or “claudin-low” subtypes, about 9% are HER2-positive, and 11% have some hormone receptor gene expression.  
 
1.1  Therapeutic options for TNBC 
Given the lack of ERs, PgRs, and HER2 receptors, options for systemic therapy in TNBC are limited. 
Chemotherapy remains the main therapeutic option for TNBC patients, since neither endocrine 
therapies nor HER2 targeted agents are effective. Due to poor prognosis and restricted therapeutic 
chances (Chacón and Costanzo, 2010; Palma et al., 2015), new targeted therapies for TNBC are 
required to improve the outcome of this subset of breast cancer. A number of agents have been and 
are being evaluated for use in TNBC.  
PARP (poly ADP ribose polymerase) is involved in repairing single-stranded DNA breaks, and it 
has therefore been hypothesized that PARP inhibition may cause cell death by preventing repair of 
mutated DNA within cancer cells. Several studies found no objective response with PARP 
inhibitors in unselected TNBC patients (Liu JF et al., 2013) 
Several studies have evaluated antiangiogenic agents, such as the VEGF inhibitor 
bevacizumab. Published data have shown that TNBC tumors express high levels of intratumoral 
Vascular Endothelial Growth Factor (VEGF) (Linderholm et al., 2009), possess high microvessel 
density (Mohammed et al., 2011) and display VEGF gene amplification compared to non-TNBC 
tumors (André et al., 2009), suggesting a marked angiogenic dependency in TNBC tumorigenesis 
and a potential sensitivity to anti-angiogenic agents. In fact, results of studies of bevacizumab in the 
neoadjuvant setting have demonstrated an improvement in pathologic complete response (pCR) rates 
(von Minckwitz et al., 2012) The treatment with the anti-VEGF monoclonal antibody (mAb) bevacizumab has 
shown some benefit when combined with standard chemotherapy (Bear et al. 2012) albeit the 
therapeutic use of bevacizumab and its clinical relevance in TNBC treatment is in the center of a 
controversy. As matter of fact, several studies demonstrated an approximate doubling of progression-
free survival (PFS) compared with placebo despite no benefit in overall survival (OS) associated with 
the use of bevacizumab was obtained (Gray R, 2009; Miles DW 2010; Robert NJ, 2011). 
One of the most exciting therapeutic developments, however, has been in the area of 
immunotherapy. Cancer immunotherapy represents a novel tool for cancer treatment based on the 
idea that stimulation of immune system may help to fight tumor. In comparison to conventional 
therapies for cancer, immunotherapy targets the immune system or tumor microenvironment rather 
than tumor cells themselves and can produce a synergistic effect in combination therapies (Whiteside 
et al., 2016).  
Immune checkpoints are crucial pathways for self-tolerance, which prevents the immune system from 
attacking cells indiscriminately. The blockade of checkpoints such as cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), programmed death 1 (PD-1) receptor and programmed death 1 
receptor ligand (PD-L1) can inhibit tumor immunoescape.  
Studies of meta-analysis indicate that PD-L1 expression was associated with positive lymph node 
metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast 
cancer (TNBC). Moreover TNBCs have high level of tumor-infiltrating lymphocytes (TIL), 
suggesting that these tumors may be particularly amenable to targeting with immune checkpoint 
inhibitors (Stanton et al., 2016). Currently, several ongoing studies are investigating the use of 
immune checkpoints, including CTLA-4 and PD-1 pathways, as potential targets of therapy for breast 
cancer in the neoadjuvant setting. Furthermore targeting PD-L1, especially within the TNBC subset, 
has been of particular interest (Yu L Y et al. 2017).  
 
1.2 The Hedgehog (Hh) signaling pathway 
The Hedgehog (Hh) signalling, initially discovered in Drosophila melanogaster, is an evolutionarily 
conserved pathway (Ingham et al., 2001); it is broadly active in early embryonic development, playing 
a crucial role in cell proliferation and differentiation, regulating angiogenesis and vascular formation 
and orchestrating tissue patterning in vertebrates and invertebrates (Van den Brink et al.,2007; Pak 
and Segal, 2016; Nagase et al., 2008) 
Later in life, Hh signaling is however inactive and, in adulthood, it presumably maintains stem cell 
populations and/or early progenitor cells.  
The key components of the mammalian Hh pathway consist of three secreted ligands (Sonic 
Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog (DHH)), a 12-pass transmembrane 
receptor (Patched (PTCH)), a  negative regulator  Suppressor of fused homolog (SUFU), a  positive 
regulatory protein Smoothened (SMO) and the glioma-associated oncogene (GLI) transcription 
factors (GLI1, GLI2 and GLI3) (Varjosalo, and Taipale, 2008) . 
 
Without the Hh signal, GLI1 and GLI2 transcription factors are sequestred by SUFU in the cytoplasm; 
the repressor factor GLI3 full lenght (gli3FL) is complexed with SUFU leading to the efficient 
processing of GLI3FL into GLI3 Repressor and the cell is maintained in a neutral state. When Hh 
signaling is initiated, ligands bind to PTCH, the inhibition of SMO by PTCH is relieved and activated 
SMO in turn initiates a downstream signalling cascade leading to the release of GLI1 transcription 
factor from SUFU-mediated cytoplasmic sequestration and activation of GLI family factors (Cohen, 
2010; Rohatgi et al., 2009); moreover SUFU dissociates from GLI3FL that translocates to the nucleus, 
where it is converted to a transcriptional activator (GLI3A). When Activated GLIs, the final effectors 
of the pathway, translocate into the nucleus bind to the GLI1-binding element in GLI1-regulated 
genes, PTCH, HIP1, D-type cyclins, BMI1, c-MYC and BCL2 which regulate cellular differentiation, 
proliferation and survival (Shahi et al., 2010; Katoh et al.,2009).  
 
Figure 2. The mammalian Hh signaling pathway: key components and signal transduction. (A) In the absence of 
Hh ligand, PTCH localizes in the cilia and represses SMO activity by preventing its trafficking and localization to the 
cilia. GLI transcription factors are sequestered in the cytoplasm by several protein mediators, including suppressor of 
fused (SUFU). GLI undergoes proteasomal cleavage and the transcription of Hh target genes is repressed. (B) Hh ligand 
interacts with PTCH; SMO activation induces dissociation between SUFU and GLI factors, that activated translocate into 
the nucleus and transcribe for Hh target genes. 
 
Components of the Hh pathway are frequently mutated in cancer and various types of Hh 
pathway activation can occur. Ligand-independent activation is due to inactivating mutations in the 
negative regulators PTCH1 or SUFU, activating mutations in SMO, or amplification of GLI 
activators. Ligand-dependent activation occurs through autocrine, paracrine or reverse paracrine 
mechanism; in autocrine mechanism tumor cells secrete and respond to HH ligands; in the paracrine 
pattern tumor cells produce HH ligands, which activate HH pathway in stroma cells; in the reverse-
paracrine mechanism stroma cells produce HH ligands, which activate HH pathway in tumor cells. 
The discovery of germline loss-of-function mutations in PTCH in patients with nevoid basal cell 
carcinoma syndrome (NBCCS) correlated Hh pathway activation and cancer. Somatic mutations in 
PTCH and gain of function mutations in SMO have been identified in basal cell carcinoma (BCC); 
these mutation have been characterized and functional studies demonstrated that they generate 
aberrant activation of Hh signaling, promoting tumorigenesis (Xie et al.,1998). In fact in 2012 a SMO 
antagonist, NVP-LDE225, was approved by the U.S. Food and Drug Administration to treat adult 
patients with metastatic basal cell carcinoma. (Sekulic et al 2012).  
Somatic mutations in PTCH, in SHH and amplification of GLI1 locus have been detected in breast 
cancer and an aberrant activation of the pathway has been described in breast cancer development 
and progression (O'Toole et al., 2011; Riku et al., 2015). Several studies demonstrate that HH 
pathway regulates the promotion of epithelial–stromal interactions (Yauch et al., 2008; Theunissen 
and de Sauvage, 2009; Angelucci et al., 2012). Emerging data support Hh pathway contribution to 
cancer cell stemness in TNBC (Habib and O'Shaughnessy, 2016).  
Furthermore, the expression of some Hh effectors, such as SMO and GLI1, is significantly increased 
in TNBC in comparison to non-TNBC (Tao et al., 2011). 
 
1.3 HH pathway and cancer microenvironment  
The cancer microenvironment consists of multiple cell populations that participate in crosstalk with 
tumor cells, regulating tumor growth and progression. The Hh pathway promotes tumor development 
and progression expecially through epitelial-stromal interaction. In ligand-dependent paracrine 
mechanisms, Hh ligands secreted by tumor cells can positively regulate Hh signaling in the 
surrounding microenvironment cells that in turn stimulates growth of the tumor. The mechanisms by 
which the Hh-stimulated stroma positively regulates tumor cell growth are not fully understood. 
However, it has been proposed that Hh regulates signaling mediators in the stroma, including insulin-
like growth factor (IGF), Wnt, vascular endothelial growth factor (VEGF) and Interleukin-6 (IL-6), 
creating a favorable cancer microenvironment .  
In cancer proliferation and metastasis process new growth in the vascular network is important 
since new blood vessels allow an adequate supply of oxygen and nutrients and the removal of waste 
products. The Hedgehog (Hh) pathway has a key role in angiogenesis and vasculogenesis during 
ontogeny. The ligand, Sonic hedgehog (SHH), plays as  an important factor in vascular formation 
during development (Hochman et al., 2006). 
Several recent data suggest the involvement of Hh signaling in tumor-associated angiogenesis: the 
ligand sonic hedgehog homolog (SHH) can promote angiogenesis in a paracrine manner, stimulating 
the production of secreted factors (Yamazaki et al., 2008). GLI1, the main transcription factor of the 
Hh pathway, leads to upregulation of a pro-angiogenic secreted molecule, cysteine-rich angiogenic 
inducer 61 (CYR61) supporting an increase in tumor vasculature (Harris et al., 2012). It has been 
demonstrated that GLI1  enhances the production of Neuropilin 2 (NRP2), a VEGFR1 and VEGFR2 
co-receptor (Goel et al., 2013).  An alternative splicing form of GLI1, 4kDa shorter than full length 
(truncated GLI1 or tGLI1), enhances the hVEGF-A gene promoter, leading to upregulation of this 
factor in breast cancer cells (Cao et al., 2012; Carpenter and Lo, 2012).  
 
Recent studies suggest that Hh signaling mediates a crosstalk between breast cancer cells and 
tumor-infiltrating immune cells (Ann et al., 2018); Hh pathway can promote the production and 
secretion of some inflammatory mediators such as IL6. IL-6 signaling acts on tumor cells to support 
cancer cell proliferation, survival, and metastatic dissemination. Moreover, IL-6 can act extrinsically 
on other cells within the tumor microenvironment to sustain tumor evasion of immune surveillance.   
Moreover treatment with systemic Hh inhibitor in BCC causes a reduction of immune-suppressive 
cells concomitant with an enrichment of cytotoxic immune cells, suggesting a novel role for Hh 
signaling in disabling anti-tumor immunity (Atsushi et al., 2015)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Study purpose  
  
The purpose of this study was to evaluate the complexity of aberrant Hh pathway functions in 
TNBC and its putative effect in sustaining TNBC microenvironment, suggesting the Hh pathway 
inhibition as new anti-angiogenic and immune-stimulating therapeutic options in this subtype of 
tumor. 
The study is divided into three tasks: 
Task 1) Evaluation of the Hh pathway activation in TNBC cancer cell lines and in TNBC patients;  
Task 2) Characterization of the Hh pathway involvement in cancer neo-angiogenesis and Task 3) 
characterization of the Hh pathway involvement in cancer immune surveillance in order to highlight 
mechanisms and markers associated to these processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Materials and Methods 
 
Compounds and cell cultures 
NVP-LDE225 and paclitaxel were purchased from Selleck Chemicals (Germany). Bevacizumab was 
kindly provided by Roche.  
For this study, a panel of immortalized (MDA-MB-361, SKBR-3, MCF7, MDA-MB-231, HCC70 
and MDA-MB-468, KPL-4, JIMT-1, 4T1) and primary (K90, K79, K193, K197) breast cancer cell 
lines were used. Besides, some experiments have been performed on endothelial cells such as human 
umbilical vein endothelial cells (HUVECs) and mouse brain endothelial cell 5 (bEND5). Human 
breast cancer cell lines MDA-MB-361, SKBR-3, MCF7, MDA-MB-231, HCC70 and MDA-MB-468 
were obtained from the American Type Culture Collection. The KPL4 cell line was isolated from the 
malignant pleural effusion of a breast cancer patient with an inflammatory skin metastasis [1]. The 
JIMT-1 cell line was established from a pleural metastasis of a 62-year-old breast cancer patient. 
Cells were routinely grown in RPMI-1640 medium with GlutaMAX supplemented with 10% fetal 
bovine serum (FBS). SUM-159 and SUM-149 human breast carcinoma cell lines were kindly 
provided by Dr. Nicola Normanno (Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori 
“Fondazione Giovanni Pascale”, IRCCS) and maintained in Ham's F12 medium with GlutaMAX 
(LifeTechnologies) supplemented with 5% FBS and 5 μg/ml insulin. Breast cancer primary cells 
(K90, K79, K193, K197) were generated by TNBC and nTNBC tumors. Briefly, tissue specimens 
were collected and processed; primary cultures were generated via standardized operative procedures 
for banking [2] and cell population expansion, as previously described [3].  
Human umbilical vein endothelial cells (HUVECs) were obtained from the American Type Culture 
Collection; mouse brain endothelial cell 5 (bEND5) were kindly provided by Dr. Mauro Cataldi 
(Dept. of Neuroscience, University of Naples Federico II). HUVEC cells were grown in F-12K 
medium, supplemented with 0.1 mg/ml heparin; 0.03-0.05 mg/ml endothelial cell growth supplement 
(ECGS), FBS.bEND5 were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% fetal calf serum, 4 mmol/L -glutamine, 1 mmol/L sodium pyruvate, 50 Units/mL penicillin, 
and 50 μg/mL streptomycin. 
 Cell lines authentications  
Short tandem repeat (STR) profiles of cell lines were obtained  using nine highly polymorphic STR 
loci plus amelogenin (Cell IDTM System, Promega). The amplified fragments were analyzed with 
the ABI PRISM 3100 Genetic Analyzer. Data analysis was performed by GeneMapper® software, 
version 4.0. Cell lines authentications was performed by IRCCS Azienda Ospedaliera Universitaria 
San Martino – Istituto Nazionale per la Ricerca sul Cancro (Genova, Italy). The cells were last tested 
inAugust 2015. 
 
Western blot analysis  
Total protein extracts obtained from cell cultures or tumor specimens were resolved by 4-15% SDS-
PAGE and probed with anti-human and anti mouse GLI11, cyclin D1, PDL1; anti human Smo, 
VEGFR2, NRP2, pAkt/Akt, pERK/ERK, bcl2 and GAPDH and anti-mouse alfa-tubulin (Cell 
Signaling Technologies, Beverly, MA, USA; Santa Cruz Biotecnology ). Immunoreactive proteins 
were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA).  
 
Capillary tube formation assay 
Twenty-four-well plates were coated with 200 μl/well of Matrigel (BD Biosciences, Billerica, MA), 
allowed to jellify for 30 min at 37°C in a cell culture incubator; HUVEC cells (5x104/well) were 
plated on top of the Matrigel in TNBC, or nTNBC conditioned growth media, or in RPMI medium 
supplemented with VEGF-A (100 ng/ml), as a positive control. Cells were observed under an inverted 
microscope Olympus CKX31 at regular intervals, and pictures were taken after 3 hours. 
 
Co-culture of tumor and endothelial cells  
The in vitro co-culture model was prepared on Transwell polycarbonate filters (surface area, 0.3 cm2; 
pore size, 0.3 μm; BD Biosciences Franklin Lakes-USA). bEND5 (2x104/well) were seeded on the 
bottom of wells in a 24-multiwell plate, were allowed to adhere for 24 hours, then TNBC or nTNBC 
cells (5x103/well) were seeded on filters. Tumor and endothelial cells were cultured together for 3 
days in DMEM medium.  
The percentage of cell density was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay according to the manufacturer’s instructions (Sigma-
Aldrich, Milan, Italy).  
 
ELISA assay for determination of VEGF-A, sVEGFR2, and THBS1 concentrations 
Anti-human VEGF polyclonal antibody (R&D Systems, Minneapolis, MN, USA), diluted at 1μg/ml 
in PBS pH 7.5, was used to coat a 96-well plate, 100 μl/well, overnight at 4°C. Washings, dilutions 
of standards (recombinant hVEGF) and samples (conditioned media from tumor cells or sera from 
sacrificed mice), biotinylation, and mixtures with preformed avidin and biotinylated HRP 
macromolecular complex (Vectastain kit) were performed as previously described (D’Amato et al., 
2014). Absorbance was measured at 490 nm on a microplate reader (Bio-Rad, Hercules, CA, USA). 
VEGF concentrations were determined by interpolation of the standard curve using linear regression 
analysis. 
sVEGFR2 and THBS1 concentrations on conditioned media from tumor cells or sera from sacrificed 
mice have been measured by using sVEGFR2 and THBS1 Quantikine ELISA kits (R&D Systems, 
Minneapolis MN, USA). 
 
Multiplexed immunoassay 
The quantitative analysis of secreted cytokines and chemokines in conditioned media (CM) of MDA-
MB-231, SUM-159, SUM-149, HCC70 and MDA-MB-468 in presence or absence of NVP-LDE225 
(2.5μM), was performed by the Bio-Plex multiplex system (Bio-Rad, Milan, Italy), based on xMAP 
technology that uses magnetic beads coated with specific antibodies raised against target analytes. 
Briefly, microspheres are internally labeled with red and infrared fluorophores. Each bead is bound 
to a specific antibody, thus allowing the simultaneous detection of multiple analytes within one 
sample. Following reaction of coupled beads with target analytes, a biotinylated antibody is added 
for the detection, which is then finalized by adding phycoerytrin-conjugated streptavidin. All steps 
were performed according to manufacturer's instructions for determining the concentration of sEGFR, 
FGF-basic, Follistatin, G-CSF, HGF, sHER-2/neu, sIL-6Rα, Leptin, PECAM-1, PDGF-AB/BB, 
Prolactin, SCF, sTIE-2, THBS1, sVEGFR-1, sVEGFR-2. Data were acquired using a Bio-Plex 
MAGPIX Multiplex Reader system equipped with a Bio-Plex Manager software v 6.1 (BioRad). All 
washing steps were performed on the Bio-Plex magnetic wash station (BioRad). Measurements were 
performed on CM samples (50 µL) using the Bio-Plex Pro human cancer biomarker panel 1 (Cat. N° 
171AC500M, BioRad) according to the manufacturer’s protocol. An aliquot of RPMI /F12/ (50 µL) 
was also analyzed as negative control. Standard curves optimization and the calculation of analyte 
concentrations were performed by using the Bio-Plex Manager software. Data were expressed as 
mean  +/- SD. A two-tailed t-test was used to test the significance between conditions by using the 
GraphPad Prism software v 5.0 (La Jolla, CA USA).  
MTT survival assay 
Cells (104 cells/well) were grown in 24-well plates and exposed for 72 hours to increasing doses of 
NVP LDE 225 or GANT61. The percentage of cell survival was determined by using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT). The half-maximal inhibitory 
concentration (IC50) for each drug was calculated by GraphPad Prism 5.0 software, normalizing the 
response between 0 and 100%. 
 
 
RNA extraction and analysis 
Total RNA was isolated from cells using TRIZOL reagent (Invitrogen). 2 μg of total RNA was reverse 
transcribed using 100 ng of random hexamer primers and Super Script III Reverse Transcriptase 
(Invitrogen). Real Time RT-PCR (qRT-PCR) experiments were performed using the CFx96 Real-
Time PCR Detection System (Bio-Rad); PCR reactions were in a final volume of 15 μl, using 5 ng 
of cDNA and iQ SYBR Green Supermix 2X (Bio-Rad). Reagents and enzymes were employed 
according to manufacturer's instructions. PCR cycling profile consisted of a cycle at 95° C for 10 min 
and 40 two-step cycles at 95° C for 10 sec and at 60° C for 60 sec. Primers were chosen using Primer3 
software (http://bioinfo.ut.ee/primer3/) and designed to span exon/exon borders; their sequences are 
listed in the Table 1. Three different RNA preparations were tested for each sample, and each reaction 
was run in triplicate.  
 
Table 1. Sequences of primers used for Real Time RT-PCR. 
GENE FORWARD SEQUENCE REVERSE SEQUENCE 
sVEGFR2 TGGTCAGGCAGCTCACAGT TCACTCTGAGTCTTCTACAAGG 
VEGFR2 TTACAGCTTCCAAGTGGCTAAGG TTAACCACGTTCTTCTCCGATAA 
THBS1 CAATGCCACAGTTCCTGATG TGGAGACCAGCCATCGTC 
PDL1  AAACAATTAGACCTGGCTG 
 
TCTTACCACTCAGGACTTG 
G6PD GAGCCAGATGCACTTCGTG GGGCTTCTCCAGCTCAATC 
β-ACTIN GAAATCGTGCGTGACATTAA AAGGAAGGCTGGAAGAGTG 
 
 
RNA interference 
Smart siRNA pool against all isoforms of GLI1 was purchased from GE Healthcare Dharmacon. A 
nonsense sequence was used as negative control. For siRNA validation, cells were transfected with 
GLI1 siRNAs (50 nmol/L) using DharmaFECT 1 Transfection Reagent in DMEM (Dharmacon); 24 
and 48 hours after transfection, western blot analysis for GLI1 and VEGFR2 expression was 
performed. 
 
Cell transfection with GLI1 expression vectors 
MDA-MB-231 and HCC70 cells were cultured in RPMI medium supplemented with 10% FBS, 100 
U/ml penicillin and 100 μg/ml streptomycin (all from Invitrogen) and grown at 37° C in a humidified 
atmosphere containing 5% CO2. For transfection, 5μg of either pCMV6-GFP GLI1, pCMV6-GFP 
tGLI1, pCMV6-GFP empty vector plasmid (Origene) were added together with lipofectamine 2000 
Reagent (Invitrogen), following the manufacturer's instructions. 
 
Luciferase Assay 
Luciferase assay was performed by using the Dual-Luciferase Assay system (Promega) following the 
manufacturer’s protocol. A total of 5x105 MDA-MB-468 cells were plated 24 hours before 
transfection in a 24-wells multiwell plate. The GLI-Luc reporter plasmid (Promega) was transfected 
together with pRL-TK, encoding the Renilla luciferase (Promega), in triplicate, using lipofectamine 
2000 Reagent (Invitrogen) with the luciferase reporter. Twenty-four hours after transfection, cells 
were treated with NVP-LDE225 5μM. Luciferase activity was determined 48 h after transfection by 
using a BioTek Microplate Luminescence Reader (BioTek, Winooski, VT, USA). 
 
ChIP assay 
The chromatin immunoprecipitation (ChIP) assay was performed in MDA-MB-468 cells using ChIP 
Assay Kit  (Millipore) following the manufacturer's instructions.  Crosslinking of the target proteins 
to the chromatin DNA with formaldehyde and breaking of the chromatin DNA into fragments (200-
1200 bp) were performed. Immunoprecipitation (IP) of the protein-DNA complex was performed 
using a GLI1 antibody (Santa Cruz Biotechnology- Heidelberg, Germany). The DNA in IP products 
was amplified by RT-PCR with ChIP assay primers specific for the VEGFR2 and PDL1 promoters. 
Results were reported as fold changes relative to input. 
 
Orthotopic breast xenograft model in nude mice 
Five-week-old Balb/cAnNCrlBR athymic (nu+/nu+) mice (Charles River Laboratories, Milan, Italy) 
maintained in accordance with institutional guidelines of the University of Naples Animal Care 
Committee and in accordance with the Declaration of Helsinki were injected into the fourth mammary 
fat pad with MDA-MB-468 cells (107 cells per mice) resuspended in 200 Pl of Matrigel (BD 
Biosciences, Billerica, MA). Seven days after the tumor cell injection, tumor-bearing mice were 
randomly assigned (n: 10 per group) to receive the following: NVP-LDE225 20 mg/kg per os every 
day for 4 weeks; bevacizumab 5 mg/kg intravenously (i.v.), twice a week for 4 weeks, or a 
combination of these agents with paclitaxel i.v. 10 mg/kg once a week for 4 weeks. Tumor diameter 
was assessed with a vernier caliper, and tumor volume (cm3) was measured using the formula 
π/6x(larger diameter)x(smaller diameter)2. Mice were killed when the tumor reached 2 cm3, the 
maximum size allowed by the ethics committee. 
 
TMA building 
A breast Tissue Micro Array (TMA) was constructed using 237 samples of TNBC collected from 
2003 to 2013 from the Pathology Unit of the Istituto Nazionale Tumori of Naples. Informed consent 
was obtained from all patients. All tumors and controls were reviewed by two experienced 
pathologists (M.D.B./G.B.) according to WHO classification criteria, using standard tissue sections 
and appropriate immunohistochemical slides. Discrepancies between two pathologists from the same 
case were resolved in a joint analysis of the cases. Moreover, all specimens were characterized for all 
routinely diagnostic immunophenotypic parameters (ER, PGR, HER2 and Ki67). TMA was built 
using the most representative areas from each single case with one replicate. Tissue cylinders with a 
diameter of 1 mm were punched from morphologically representative tissue areas of each ‘donor’ 
tissue block and brought into one recipient paraffin block (3 × 2.5 cm) using a semi-automated tissue 
arrayer (Galileo TMA). 
 
Immunohistochemical analysis  
For immunoistochemical analysis on mice tumor specimens, excised tumors were split into two 
halves and immediately fixed in 10% buffered formalin solution. Twelve hours later, tissues were 
embedded in paraffin in an automated tissue processor. Sections (4-5 μm) were then cut with a serial 
microtome and mounted on adhesive poly-L-lysine-coated slides. After being dried in an oven at 40° 
C for 8 hours, the slides were processed for immunohistochemistry (IHC) in a semi-automated 
machine (Menarini Bond Max, Menarini, Florence, Italy) with the following antibodies: CD31, GLI1, 
NRP2, VEGFR2 and PDL1 (Novocastra, Newcastle, United Kingdom).  
Immunohistochemical staining on TMA slides was done from formalin-fixed, paraffin embedded 
tissues to evaluate the expression of GLI1, VEGFR2 and PDL1 markers in human tumors. For PDL1 
presence or absence of staining was evaluated (positive or negative expression).  There are not 
standardized criteria for VEGFR2 and Gli1 markers staining evaluation. The staining intensity was 
graded as follows: 0, negative; 1, weak; 2, moderate; and 3, intense; the proportion was graded 
according to the percentage of positive cells as follows: 0, negative; 1, 1-14%; 2, t15%. The intensity 
score and proportion score were multiplied in order to generate an immunoreactive score (IS). IS 0 
defines negative expression, IS ranging between 1 and 3 defines moderate expression and IS greater 
than 3 high expression. 
 
 
 
 
4. Results  
4.1 Task 1:  
GLI1 is frequently overexpressed in TNBC primary and immortalized cell lines.  
We investigated the expression of the main Hh pathway transducers in ten human breast cancer cell 
lines, five ER/PgR+ and/or HER2+ (nTNBC) and five ER/PgR- and HER2- (TNBC). None of the 
cell lines used display mutations in the major Hh signaling components; the molecular features of the 
selected cell lines are depicted in Table 2.  
 
Table 2. Clinicopathological features of the human breast cancer cell lines included in the study.  
                       
 
The expression of SMO and mostly GLI1 was higher in TNBC cell lines (Fig. 3A).  Similar results 
have been obtained in primary breast cancer cell lines, generated from two ER+ breast cancer patients 
and two triple negative ones: overexpression of GLI1, as well as of its truncated form tGLI1, was also 
evident in these models (Fig. 3B). The HH pathway ligands Desert Hedgehog (DHH), Indian 
Hedgehog (IHH) and Sonic Hedgehog (SHH) showed comparable expression in all the analyzed 
cancer cell lines (Fig. 3C). 
 
 
 
Figure 3. GLI1 is frequently overexpressed in TNBC primary and immortalized cell lines.  
(A, B) Western blot analysis of protein expression in a panel of (A) nTNBC or TNBC immortalized cell lines, and (B) 
nTNBC or TNBC primary cell lines. (C) HH ligands expression in conditioned media of immortalized cells. ELISA assay 
for the determination of IHH, DHH and SHH concentrations (ng/ml) in conditioned media from nTNBC or TNBC 
immortalized cells. Data represent the mean (±SD) of three independent experiments, each performed in triplicate.  
 
 
 
GLI1 expression in TNBC patients  
To evaluate the relevance of Hh pathway activation in triple negative breast cancer (TNBC), we 
analyzed a TNBC TMA by immunohistochemistry. The patient cohort included 237 TNBC samples 
of breast cancers; the age of patients ranged from 24 to 93 years (average age = 57 years). Clinical-
pathological characteristics and follow-up data of TNBC patients are depicted in Table 3.  
 
Table 3. Clinical-pathological characteristics and follow-up data of TNBC patients included in 
the TMA 
    Grade  
 
11.8% 
82.8% 
5.4% 
Metastatic lymph nodes 
(LNM) 
 
grade I-II 
grade III 
not available 
positive 
negative 
not available 
34.0% 
46.6% 
19.4% 
Tumor size  
42.9%  
43.3% 
8.4% 
5.4% 
Ki67 expression  
< 2 cm 
2 – 5 cm 
> 5 cm 
not available 
high 
low 
not available 
78.2% 
17.6% 
4.2% 
Distant metastases  
17.6% 
55.0% 
27.4% 
 
positive 
negative 
not available 
       
The evaluated cases were 200/237. Tumor samples were classified based on the Immunoreactive 
Score (IS, see Methods section). As shown in 24/200 cases (12.0%) there was a high GLI1 expression 
(IS>3), in 53/200 cases (26.5%) there was a moderate expression (1<IS<3) and in 123/200 cases 
(61.5%) there was no GLI1 expression with IS equal to 0 (Fig. 4A).  
 
4.2 Task2:  
GLI1 expression correlates with VEGFR2 in TNBC patients  
VEGFR2 expression was assessed in all samples evaluated for GLI1 expression: as shown in figure 
4B, 9/200 TNBC samples (4.5%) showed high expression for VEGFR2 (IS>3), 20/200 (10.0%) 
showed moderate expression (1<IS<3), while 171/200 cases (85.5%) resulted negative (IS=0). 
Considering the 20 samples with VEGFR2 IS ranging from 1 to 3, 7/20 cases (35.0%) were negative 
for GLI1 expression (IS=0), 9/20 (45.0 %) showed moderate expression for GLI1 (1<IS<3) and 4/20 
(20.0 %) showed GLI1 high expression (IS>3). Notably, among the 9 samples showing VEGFR2 
IS>3, all showed IS>3 also for GLI1 (100.0 %). Statistical analysis demonstrated a direct significant 
association between VEGFR2 and GLI1 expression in TNBC patients (P = 0.000, R Pearson = 0.489), 
as shown in Table 4. 
 
 
 
  
Figure 4. GLI1 expression correlates with VEGFR2 in TNBC patients. 
(A) Left, pie chart representing the percentage of samples included in the TMA that show IS equal to 0, 1<IS<3 and IS>3 
for GLI1 expression, respectively. Right, immunoistochemical images representing GLI1 negative (IS=0) or positive 
tumors with moderate (1<IS<3) or high (IS>3) expression levels, respectively (20X magnification). The red arrows 
indicate representative highly GLI1 positive signal. (B) Left, pie chart representing the percentage of samples included in 
the TMA that show Immunoreactive score (IS) equal to 0, 1<IS<3 and IS>3 for VEGFR2 expression. Right, 
immunoistochemical images representing VEGFR2 negative (IS=0) or positive tumors with moderate (1<IS<3) and high 
(IS>3) expression levels, respectively. Endothelial cells positivity represents internal control (20X magnification). The 
red arrows indicate representative highly VEGFR2 positive signal.  
 
 
 
 
 
 
Table 4. Correlation between GLI1 and VEGFR2 expression in TNBC patients. 
 
 
 
 
 
 
 
 
Hh pathway regulates the production of pro- and anti-angiogenic secreted factors. 
Interestingly, the triple-negative condition of cell models, used in the study, seems to influence tumor 
angiogenesis, as demonstrated by capillary tube formation assay performed with HUVEC cells grown 
in conditioned media from cultured MDA-MB-361 (nTNBC) or MDA-MB-468 (TNBC) cells. 
Medium from TNBC cells strongly promoted the endothelial cells ability to form capillary structures; 
the stimulation was comparable to that obtained by treatment with VEGF-A (Fig. 5A). In order to 
better evaluate the effect of tumor cells on endothelial cell proliferation, co-cultures of mouse brain 
endothelial cells bEND5 and breast cancer cell lines were performed. As shown in figure 5B, TNBC 
cells promoted bEND5 proliferation in a stronger manner than nTNBC; consistent with this finding, 
TNBC cell lines (Fig. 5C), as well as TNBC primary cells (Fig. 5D) secreted higher levels of VEGF-
A compared to nTNBC ones.   
    GLI1   
    IS = 0 1 < IS < 3 IS > 3   
 V
E
G
FR
2 
IS = 0 116  44 11      P value           R Pearson 
  
         0.000                0.489 1 < IS < 3 7/20  
(35.0%) 
9/20 
 (45.0%) 
4/20 
(20.0%) 
IS > 3 0/9  
(0.0%) 
0/9 
 (0.0%) 
9/9 
 (100.0%) 
  
  
Figure 5. Hh pathway and in vitro angiogenesis. (A) Capillary tubes formation assay on HUVEC cells grown on 
Matrigel in: RPMI serum free medium; RPMI serum free medium supplemented with VEGF-A (100 ng/ml); conditioned 
growth media from nTNBC (MDA-MB-361) or TNBC (MDA-MB-468). Cells were observed under an inverted 
microscope, and pictures were taken at T0 hours and after 3 hours. Scale bars, 100μm. (B) Percent of cell density of 
bEND5 endothelial cells co-cultured with nTNBC or TNBC cells for 3 days, as measured by MTT assay. Data represent 
the mean (±SD) of three independent experiments, each performed in triplicate. (C, D) ELISA assay for determination of 
VEGF-A concentrations (pg/ml) in conditioned media from (C) nTNBC or TNBC immortalized cells, or (D) primary 
cells. Data represent the mean (±SD) of three independent experiments, each performed in triplicate.  
 
To investigate the putative role of Hh activation in TNBC dependent regulation of tumor 
angiogenesis, the effects of Hh pathway inhibition on angiogenesis have been compared with those 
obtained with bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb) (Ferrara et al., 
2004). To this aim, we used the selective SMO antagonist NVP-LDE225, a clinically approved drug 
for the treatment of basal cell carcinoma (BCC) (Sekulic et al., 2012; Rudin, 2012). A capillary tube 
formation assay was performed using HUVEC cells grown in the conditioned medium of MDA-MB-
468 treated with NVP-LDE225 or bevacizumab: NVP-LDE225 treatment discouraged endothelial 
cells organization in capillary tubes in a more effective manner than bevacizumab (Fig. 6A). 
Conversely, bevacizumab determined a reduced presence of secreted VEGFA in culture medium 
compared to NVP-LDE225 treatment, as shown in figure 6B.  
The paracrine effect of Hh pathway inhibition by NVP-LDE225 on tumor microenvironment was 
also evaluated in vivo, in Balb/C nude mice orthotopically xenografted with MDA-MB-468 cells and 
treated with NVP-LDE225 or bevacizumab. Two weeks after starting treatments, mice were 
sacrificed, and the expression of the angiogenic marker CD31 on tumor tissue was evaluated trough 
immunofluorescence analysis (figure 6C). NVP-LDE225 appears to be more effective in inhibiting 
angiogenesis than bevacizumab. Based on these data, we hypothesized that Hh inhibition could lead 
to dysregulation of some uncharacterized secreted factors, able to regulate tumor angiogenesis. 
Therefore, a multiplex ELISA assay for 16 secreted factors was conducted on TNBC media upon 
treatment of TNBC cultured cells with NVP-LDE225. Levels of soluble VEGFR2 (sVEGFR2) and 
thrombospondin1 (THBS1) significantly increased in TNBC cell supernatants after NVP-LDE225 
treatment (Fig. 6D, 6E); sVEGFR2 and THBS1 mRNA levels were augmented as well (Fig. 6F, 6G). 
These data have been confirmed by ELISA assays specific for each analyte (data not shown). These 
findings are of interest since sVEGFR2 and THBS1 are known as two endogenous angiogenesis and 
lymphangiogenesis inhibitors (Nyberg et al., 2005). 
 
 
 
Figure 6. Hh pathway regulates the production of pro- and anti-angiogenic secreted factors. 
(A) Capillary tubes formation assay on HUVEC cells grown on Matrigel in presence of conditioned growth media of 
TNBC (MDA-MB-468) cells treated with NVP-LDE225 (2.5 µM) or bevacizumab (1 µM).Cells were observed under an 
inverted microscope, and pictures were taken at T0 hours and after 3 hours. Scale bars, 100μm. (B) Quantitative analysis 
of VEGF-A in conditioned media (CM) of MDA-MB-231, SUM-159, SUM-149, HCC70 and MDA-MB-468 cells treated 
with NVP-LDE225 (2.5 μM) or bevacizumab (1 µM). (C) Expression of CD31 protein (red) in tumor tissues from nude 
mice xenografted with TNBC tumors, as measured by immunofluorescence analysis on day 21, after two weeks of 
treatment with NVP-LDE225 or bevacizumab. Nuclei are stained in blue (DAPI). Merged row images show overlapping 
of CD31 and DAPI signals. Scale bars, 75 μm.  
 (D, E) Quantitative analysis of (D) sVEGFR2 and (E) THBS1 in CM of MDA-MB-231, SUM-159, SUM-149, HCC70 
and MDA-MB-468 cells treated with NVP-LDE225 (2.5 μM), as performed by using a multiplexed immunoassay. (F, G) 
Relative expression of (F) sVEGFR2 and (G) THBS1 mRNA in MDA-MB-231, SUM-159, SUM-149, HCC70 and 
MDA-MB-468 treated with NVP-LDE225 (2.5 μM), as performed by Real Time RT-PCR (qRT-PCR) analysis. Data 
were calculated with mean cycle threshold (CT) values, normalized to endogenous control. Data represent the mean (±SD) 
of three independent experiments, each performed in triplicate. Bars, SDs. Asterisks indicate statistical significance, as 
determined by the Student t-test (*P < 0.05, **P < 0.01,***P < 0.001).  
 
GLI1 regulates VEGFR2 expression. 
To investigate the capability of Hh pathway to modulate components of the angiogenic machinery, 
expression of VEGFR2 has been measured: after treatment with NVP-LDE225 a reduction of protein 
and mRNA levels was observed in both MDA-MB-468 and HUVEC cells (Fig.7A, 7B), an event 
paired with a simultaneous reduction of NRP2, as already known (Goel et al., 2013). Therefore, we 
hypothesized that Hh could be involved in the transcriptional modulation of the VEGFR2 receptor, 
eventually mediated by GLI1. To address this issue, GLI1/tGLI1 silencing was performed in MDA-
MB-468 and HUVEC cells using a siRNA pool for all GLI1 forms. As depicted in figure 7C, GLI1 
silencing caused down-regulation of VEGFR2 protein expression. Then GLI1 and tGLI1 
overexpressions were performed in MDA-MB-231, a TNBC cell line with a low endogenous 
expression of GLI1. The levels of VEGFR2 protein augmented when tGLI1 was overexpressed, as 
shown in figure 7D. A bioinformatic analysis looking for a known GLI1/tGLI1-binding site (Kinzler 
and Vogelstein, 1990) revealed two putative sequences within ≈ 500 bp upstream of VEGFR2 
transcription start site (Fig. 7E). Therefore, we carried out a luciferase reporter assay. As shown in 
figure 7F, VEGFR2 gene promoter is activated in GLI1 overexpressing MDA-MB-468 cells, and 
NVP-LDE225 treatment significantly abrogates its activity (P value < 0.001). To further validate the 
functional GLI1/VEGFR2 promoter interaction, we performed a chromatin immunoprecipitation 
analysis following by PCR amplification of four different regions (P1 to P4) of VEGFR2 gene 
promoter (Fig. 7E). We found that tGLI1 binds the VEGFR2 promoter, especially in the P3 region, 
confirming that tGLI1 transcriptionally enhances VEGFR2 (Fig. 7G). The graphical representation 
of tGLI1 binding site on VEGFR2 promoter region is shown in the figure 7H. The down-regulation 
of VEGFR2 observed upon NVP-LDE225 could be related to an interference with GLI1 intracellular 
localization, since NVP-LDE225 can reduce nuclear translocation of GLI1 and to increase its 
cytoplasmic retention, as demonstrated by western blot and immunofluorescence assays (Fig. 8A, 
8B).  
 
Figure 7. GLI1 regulates VEGFR2 expression. 
(A) Western blot analysis of protein expression in MDA-MB-468 and HUVEC cells treated with NVP-LDE225 (2.5 μM). 
(B) Relative expression of sVEGFR2 mRNA in MDA-MB-468 and HUVEC cells treated with NVP-LDE225 (2.5 μM), 
as performed by Real Time RT-PCR (qRT-PCR) analysis. Data were calculated with mean cycle threshold (CT) values, 
normalised to endogenous control. Data represent the mean (±SD) of three independent experiments, each performed in 
triplicate. (C) Western blot analysis of protein expression in MDA-MB-468 and HUVEC cells, 24 and 48 hours after 
transfection with scramble or GLI1 siRNA pool (50 nmol/L) using DharmaFECT 1 Transfection Reagent in DMEM. (D) 
Western blot analysis of protein expression in MDA-MB-231 cells, 24 hours after transfection with either pCMV6-GFP 
empty vector, pCMV6-GFP GLI1, or pCMV6-GFP tGLI1 plasmids using lipofectamine 2000 in DMEM. (E) Putative 
GLI1/tGLI1-binding sites within VEGFR2 gene promoter: two putative GLI1/tGLI1-binding sites upstream of VEGFR2 
transcription start site (ATG, in red) are highlighted in grey. Sequence of VEGFR2 gene promoter is represented, 
highlighting the four regions (P1 to P4) used for ChIP assay. 
 (F) Relative luciferase units in MDA-MB-468 cells transfected with the empty pGL4 plasmid or the pGL4 plasmid 
containing 500 bp fragment of VEGFR2 promoter, and treated with NVP-LDE225 5 μM 24h after transfection. Luciferase 
activity was determined 48h after transfection. Results were the average of three independent experiments. (G) Chromatin 
immunoprecipitation (ChIP) assay in MDA-MB-468 cells by using a GLI1 antibody and primers specific for the VEGFR2 
promoter. Results were reported as fold change compared to negative control (no antibody); results were the average of 
three independent experiments. Bars, SDs. Asterisks indicate statistical significance, as determined by the Student t-test 
(**P < 0.01). (H) Graphical representation of VEGFR2 proximal promoter region, containing the binding site of tGLI1 
indicated by oval.  
 
                
Figure 8. NVP-LDE225 treatment reduces nuclear translocation of GLI1 and increases its cytoplasmic retention. 
(A) Western blot analysis of GLI1 on nuclear and cytoplasmic protein extracts from MDA-MB-468 treated with NVP-
LDE225 (2.5 µM). β-actin was used as cytoplasmic marker. (B) Intracellular localization of GLI1 protein (green) in 
MDA-MB-468 treated with NVP-LDE225 (2.5 µM), as analyzed by immunofluorescence analysis. Nuclei are stained in 
blue (Hoechst). Merged row images show overlapping of Gli1 and Hoechst signals. Scale bars, 15 μm. 
 
 
NVP-LDE225 increases the efficacy of paclitaxel in nude mice xenografted with TNBC tumors.  
Pharmacological inhibition of Hh in vitro simultaneously reduces the expression of pro-angiogenic 
receptors and increases the production of anti-angiogenic secreted factors both in endothelial and 
TNBC cells. To analyze the overall effect of these findings, an in vivo experiment was performed in 
Balb/C nude mice orthotopically xenografted with MDA-MB-468 cells. We compared the effects of 
NVP-LDE225 with bevacizumab, each of them combined with paclitaxel; the last combination 
represents the current standard of care for TNBC patients (Herold and Anders, 2013). As reported in 
figure 9A, untreated mice reached the maximum allowed tumor size, ca. 2 cm
3
, on day 63; at this 
time point, NVP-LDE225 plus paclitaxel and bevacizumab plus paclitaxel produced 55% and 29% 
of growth inhibition, respectively. Notably, the combination of NVP-LDE225 and paclitaxel caused 
a long-lasting antitumor activity, with a tumor size of 1.64 cm3 at the end of the experiment, whereas 
bevacizumab plus paclitaxel treated mice reached the maximum allowed tumor size on day 84. 
Comparison of tumor sizes, evaluated by the one-way ANOVA test, was statistically significant for 
the combination NVP-LDE225 and paclitaxel vs. control (P ≤ 0.05; Fig. 9A). Consistently, as shown 
in figure 9B, mice treated with NVP-LDE225 and paclitaxel showed a slightly prolonged median 
survival compared with those treated with bevacizumab and paclitaxel, since 20% of NVP-LDE225-
paclitaxel treated mice were still alive at the end of the experiment. Median survival in the NVP-
LDE225 plus paclitaxel treated mice was significantly longer than in control mice (79.50 vs. 53.50 
days, P = 0.0089) (Fig. 9B and Table 5). NVP-LDE225 based treatment was well tolerated; no weight 
loss or other signs of acute or delayed toxicity were observed. Western blot analysis of tumors from 
mice sacrificed on day 21, after 2 weeks of treatment, demonstrated that NVP-LDE225 combined 
with paclitaxel efficiently interfered with Hh-dependent signal transduction by reducing expression 
of cyclin D1 and Bcl2, both direct targets of GLI1 (Fig. 9C). Interestingly, NVP-LDE225 plus 
paclitaxel treatment was effective in reducing VEGFR2 and augmenting sVEGFR2 expression, 
consistently with in vitro findings (Fig. 9C). Furthermore, NVP-LDE225 combined with paclitaxel 
was able to reduce human VEGF-A in mice serum (Fig. 9D).  Conversely, an overexpression of 
THBS1 was found in sera collected from NVP-LDE225 plus paclitaxel treated mice (Fig. 9E). The 
treatment induced sVEGFR2 secretion by both stromal (mouse sVEGFR2) and tumor cells (human 
sVEGFR2) (Fig. 9F, 9G).  
Immunoistochemical analysis on tumors from mice sacrificed on day 21, after 2 weeks of treatment, 
demonstrated that NVP-LDE225 combined with paclitaxel interferes with angiogenesis in nude mice 
xenografted with TNBC tumors. In fact, the combination NVP-LDE225 plus paclitaxel reduced the 
expression of VEGFR2, NRP2, and CD31, as well as of the proliferation marker Ki67, more 
efficiently than the combination bevacizumab plus paclitaxel (Fig. 10).  
 
 Figure 5. NVP-LDE225 increases efficacy of paclitaxel in nude mice xenografted with TNBC tumors.  
(A) Tumor volume of MDA-MB-468 orthotopic xenografts in nude mice, randomized (10/group) to receive NVP-
LDE225 or bevacizumab in combination with paclitaxel, as described in the Methods section. The one-way ANOVA test 
was used to compare tumor sizes among treatment groups at the median survival time of the control group (35 days). 
Comparison of tumor sizes, evaluated by the one-way ANOVA test, was statistically significant for the combination 
NVP-LDE225 and paclitaxel vs control (P ≤ 0.05). (B) Number of surviving mice orthotopically xenografted with MDA-
MB-468, after treatments with NVP-LDE225 or bevacizumab in combination with paclitaxel, as described in the Methods 
section. Median survival differences were statistically significant Median survival in the NVP-LDE225 plus paclitaxel 
treated mice was significantly longer than in control mice (79.50 vs 53.50 days, P = 0.0089, log-rank test). (C) Western 
blot analysis on total lysates from MDA-MB-468 tumor specimens of mice sacrificed on day 21, after two weeks of 
treatment with NVP-LDE225 or bevacizumab in combination with paclitaxel. (D, E, F, G) ELISA assay for determination 
of (D) hVEGF-A, (E) hTHSB1, (F) hsVEGFR2 and (G) msVEGFR2 concentrations (pg/ml) in mice sera, collected on 
day 21. Data represent the mean (±SD) of three independent experiments, each performed in triplicate.  
Bars, SDs. Asterisks indicate statistical significance, as determined by the Student t-test (*P < 0.05, **P < 0.01). 
                          
Figure 10. NVP-LDE225 treatment interferes with angiogenesis in nude mice xenografted with TNBC tumors. 
Immunohistochemical analysis of MDA-MB-468 tumor specimens of mice sacrificed on day 21, after two weeks of 
treatment with NVP-LDE225 or bevacizumab in combination with paclitaxel, as described in the Methods section. H/E: 
haematoxylin/eosin staining. Scale bars, 100μm. 
 
 
 
 
 
 
Table 5. Comparison of survival curves in nude mice xenografted with TNBC tumors.   
  
Log-rank (Mantel-Cox) Test  
Chi square 6.847 
df 1 
P value 0.0089 
P value summary ** 
Are the survival curves sig different? Yes 
Median survival  
NVP-LDE225 + paclitaxel 79.50 
Control 53.50 
Ratio 1.486 
95% CI of ratio 1.091 to 1.881 
Hazard Ratio  
Ratio 0.2225 
95% CI of ratio 0.07221 to 0.6858 
 
 
4.3 Task 3:  
GLI1 expression correlates with PDL1 in TNBC patients  
Recent studies demonstrated TNBCs are more immunogenic compared to the other breast cancer 
types and express higher levels of PDL1 than nTNBCs (Issam et al., 2018). Since our findings 
suggested Hh pathway activation in TNBC compared to non TNBC, we explore the potential link 
beetween tumor-immune microenvironment of TNBC and Hh signaling.  
To evaluate the correlation of Hh pathway activation and PDL1 expression,  PDL1 expression was 
assessed in the TNBC TMA previously evaluated for GLI1 expression. The evaluable cases in which 
we can analyze both PDL1 and GLI1 protein were 203/237. As shown in 77/203 cases (38.0%) there 
was a positivity for PDL1 expression; 126/203 cases (62.0%) were negative for PDL1 expression. 
Notably, among the 77 PDL1-positive samples, 42/77 were also positive for GLI1 (54.5%). Statistical 
analysis demonstrated a direct significant association between PDL1 and GLI1 expression in TNBC 
patients (P = 0.000, R Pearson = 0.000), as shown in Table 6. 
Furthermore we interrogated the open-access database cBioPortal for Cancer Genomics in order to 
explore correlations between other Hh pathway members and PDL1 in TNBCs ; as shown in figure 
10 A and 10 B. SMO and PTCH1 mRNA are significantly overexpressed in PDL1 positive TNBCs  
(Q-value 0.018 and 0.010) . 
 
Table 6.  Correlation of GLI1 with PDL1 in TNBC TMA. 
 
 
 
Figure 10.  Correlation of SMO and PTCH1 with PDL1. The interactive correlations between SMO, 
PTCH1 and PDL1 were evaluated interrogating the open-access cBioPortal data sets.  
 
GLI1 regulates PDL1 expression in TNBC cell lines. 
To investigate the capability of Hh pathway to modulate components of immune check-point, the 
expression of PDL1 has been measured: after treatment with NVP-LDE225 a reduction of protein 
and mRNA levels was observed in all TNBC cell lines evaluated (Fig. 11A, 11B). The NVP-LDE225 
pharmacological modulation of PDL1 protein and RNA was evaluated also in MDA-MB-468 tumor 
specimens of previous in vivo experiment (Fig. 11C, 11D). We hypothesized that Hh could be 
involved in the transcriptional modulation of the PDL1, eventually mediated by GLI1. To address 
this issue, GLI1 overexpression was performed in MDA-MB-231, a TNBC cell line with a low 
endogenous expression of GLI1. The levels of PDL1 protein increased slightly when GLI1 was 
overexpressed, probably due to high basal levels of endogenous PDL1 as shown in figure 11E. 
Therefore GLI1 overexpression was induced in HCC70 cell lines, a TNBC model with lower 
endogenous level of both GLI1 and PDL1 than other TNBC cells. As shown in figure 11F, PDL1 
protein clearly augmented when GLI1 was overexpressed. A bioinformatic analysis looking for the 
promoter regions for PDL1 revealed two regulatory regions upstream of VEGFR2 transcription start 
site (Fig. 11G). To evaluate the functional GLI1/PDL1 promoter interaction we carried out a 
chromatin immunoprecipitation analysis for GLI1 followed by PCR amplification of two different 
regions (P1 and P2) of the PDL1 gene promoter. We found that GLI1 binds the PDL1 promoter, 
especially in the P1 region. To confirm that GLI1 transcriptionally enhances PDL1 a luciferase 
reporter assay will be performed (fig. 11H).  
The expression of GLI1 was evaluated in 4T1 cells, a TNBC murine model that when injected into 
BALB/c mice spontaneously produces highly metastatic tumors. As shown in figure 12A , 4T1 cells 
viability was inhibited by NVP LDE 225 treatment in a dose-dependent manner; also the treatment 
with GANT61, a direct GLI1 antagonist, decreased 4T1 cells proliferation(Fig.12B). NVP-LDE225 
treatment was effective in reducing PDL1 protein expression as well as cyclin D1, well-known target 
of GLI1 (Fig.12C). To analyze the overall effect of these in vitro findings, an in vivo experiment will 
be performed in Balb/C mice orthotopically xenografted with 4T1 cells.  
 
 
Figure 11. Hh pathway modulates PDL1 expression in TNBC cell lines. (A) Western blot analysis of 
protein expression in TNBC cells treated with NVP-LDE225 (2.5 μM). (B) Relative expression of PDL1 mRNA in TNBC 
cells treated with NVP-LDE225 (2.5 μM), as performed by Real Time RT-PCR (qRT-PCR) analysis. Data were calculated 
with mean cycle threshold (CT) values, normalised to endogenous control. Data represent the mean (±SD) of three 
independent experiments, each performed in triplicate. (C-D) Western blot analysis of protein expression  in MDA-MB-
468 tumor specimen after 21 days of NVP-LDE225 treatment in in vivo experiment (D) Relative expression of PDL1 
mRNA in MDA-MB-468 tumor specimen after 21 days of NVP-LDE225 treatment in in vivo experiment . (E-F) Western 
blot analysis of protein expression in MDA-MB-231 cells (E) and in HCC70 (F), 24 hours after transfection with either 
pCMV6-GFP empty vector, pCMV6-GFP GLI1 plasmids using lipofectamine 2000 in DMEM. (G) two regulatory 
promoter region of PDL1 gene are highlighted in red and named P1 and P2.  
 (H) Chromatin immunoprecipitation (ChIP) assay in MDA-MB-468 cells by using a GLI1 antibody and primers specific 
for the PDL1 promoter. Results were reported as fold change compared to negative control (IgG antibody); results were 
the average of three independent experiments. Bars, SDs. Asterisks indicate statistical significance, as determined by the 
Student t-test.   
 
    
 
 
Figure 12. Hh pathway inhibition exerts antiproliferative effects on 4T1 breast cancer cells. (A) Effects of NVP-
LDE225 and (B) GANT61 treatment on 4T1 cells  viability measured by MTT assay, (C) Western blot analysis of 
protein expression in 4T1 cells treated with NVP-LDE225 (2.5 μM).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5. Discussion 
 
Breast cancers which lack the expression of ER, PgR, and HER2 receptors are grouped and defined 
as TNBCs. Owing to the lack of targeted therapies, these cancers are uniformly treated with 
chemotherapy (Cleator and Heller, 2007); nevertheless, outcomes are poor compared with those of 
other subtypes (Mustacchi and De Laurentis, 2015).  
Despite considered a single entity from a clinical perspective, TNBC is a heterogeneous disease which 
comprises distinct molecular subtypes (Bose, 2015). The difficulties encountered to identify several 
targetable molecules in TNBC are based on common and wrong idea of TNBC as a single entity. In 
the last decade research efforts have focused on sub-divided TNBC in smaller groups, bearing similar 
molecular features and sharing uniform oncogenic behaviour (Pareja F et al, 2016; Shah et al., 2012). 
Higher expression of different biomarkers including VEGFR, epidermal growth factor receptor 
(EGFR) and fibroblast growth factor receptor (FGFR), has given the rationale for clinical trials 
assessing the role of targeted inhibitors to these pathways in triple-negative tumors (Andreopoulou et 
al., 2012). Results from these trials have shown some benefit in small subgroups of patients, which 
reflects the heterogeneity of TNBC (Arnedos et al., 2012) and highlights the need for a further sub-
classification of these tumors for better prognosis assessment and treatment individualization.  
Furthermore there are growing evidences that TNBCs, characterized by a high level of immune cells 
infiltration,  are more immunogenic compared to other breast cancers, encouraging researchers to 
investigate TNBC response to immune check-point inhibitors. The complex interactions between 
TILs and tumor cells in TNBC represent an area of interest and remain not well characterized. 
Several studies suggest the involvement of Hh pathway in breast cancer (O'Toole et al., 2011), 
although the functional significance of these findings and their potential therapeutic impact is unclear. 
In our work, we found that TNBC cells overexpress the Hh family transcription factors GLI1 and 
tGLI1. In a tissue microarray analysis on 200 TNBC patients, about 12% and 26% of patients 
expressed the GLI1 protein at low and moderate levels, respectively.  
Since it is known that the Hh pathway promotes cancer progression influencing the surrounding 
microenvironment through epithelial-stromal interaction (Yauch et al., 2008; Theunissen and de 
Sauvage, 2009; Heller et al., 2012), we deeply explored the effect of GLI1/tGLI1 overexpression in 
TNBC initiated angiogenesis and we began to characterize the function of Hh pathway in TNBC 
immune escape mechanisms.  
Interestingly, a statistically significant association between VEGFR2 and GLI1 expression was found 
in TNBC patients. In in vitro experiments we highlighted that overexpressing GLI1 cancer cells 
influenced endothelial cells proliferation and their capability to form capillary, in part regulating the 
VEGF-A production as previously described. Despite Hh inhibition depressed VEGF-A secretion less 
efficiently than the anti-VEGF monoclonal antibody bevacizumab, we found that NVP-LDE225 
discouraged capillary organization in a more evident manner. With the intent to demonstrate that the 
Hh pathway could regulate tumor angiogenesis in both VEGF-dependent and VEGF-independent 
manners, we found an upregulation of sVEGFR2 and THBS1 after pharmacological Hh pathway 
inhibition. sVEGFR2 represents a VEGFR2 splicing variant identified as an endogenous inhibitor of 
lymphangiogenesis; it acts as a decoy receptor, sequestering VEGF from VEGFR-2 binding 
(Albuquerque et al., 2009; Shibata et al., 2010). THBS1 represents a natural anti-angiogenic secreted 
factor (Lawler, 2002; Henkin and Volpert, 2011). Collectively, the reduction of VEGF-A, coupled 
with the upregulation of sVEGFR2 and THBS1, could explain the deeper antiangiogenic in vitro 
effect of NVP-LDE225 compared to bevacizumab, since the latter is able to only suppress VEGF-A 
activated angiogenesis. Simultaneously with the increase of sVEGFR2, reduced levels of VEGFR2 
protein and mRNA were found after Hh inhibition, thus suggesting a putative regulation of VEGFR2 
expression by Hh. As hypothesized by bioinformatic analysis, we demonstrated a functional 
interaction between tGLI1 and the VEGFR2 promoter, demonstrating a transcriptional modulation of 
the VEGFR2 receptor mediated by tGLI1. 
These findings suggest that GLI1/tGLI1 overexpressing cancer cells promote tumor progression in a 
paracrine manner. They can orchestrate tumor vascularization not only by inducing VEGF-A 
secretion but also by upregulating VEGFR2 on cancer cell surface, thus establishing a secreted 
factors/receptors autocrine loop. The Hh pathway could regulate other angiogenic receptors: for 
instance, Lal Goel and colleagues demonstrated that GLI1 sustains a NRP2/α6β1 integrin based 
autocrine loop through enhanced NRP2 expression (Goel et al., 2013). Increased production of 
THBS1 and sVEGFR2 strengthens the anti-angiogenic effects observed upon Hh inhibition. 
Collectively, our data suggest that HH pathway activation in TNBC cellular models acts on tumour 
angiogenesis in a wide manner and at multiple levels.  Promoting production and interactions between 
several pro-angiogenic secreted or receptor factor, HH signalling is able to equip the TNBCs of 
vascular structures that facilitate tumor progression and metastasis. Therefore, it is possible that Hh 
pharmacological inhibition discourages the pro-angiogenic behavior of TNBC.  
These data are in part confirmed by the finding that, in tumor samples of TNBC patients, VEGFR2 
expression correlated with GLI1 expression. This co-expression reflects the functional connection 
between the transcriptional factor and the receptor identified in in vitro analysis. Therefore, co-
expressing GLI1 and VEGFR2 TNBC might be considered a new subgroup in which Hh pathway 
inhibition could be clinically investigated because of its effects on both cancer cells and tumor 
microenvironment. 
To evaluate the translational relevance of these findings, the combinations of paclitaxel with either 
NVP-LDE225 or bevacizumab were tested in TNBC xenografted mice. Whereas bevacizumab 
administration remains controversial, especially because of small clinical benefits and high costs 
associated, its combination with paclitaxel represents the canonical schedule for TNBC treatment. By 
scheduling NVP-LDE225 rather than bevacizumab, we attempted to demonstrate the therapeutic 
advantage of this combination. In line with the findings that NVP-LDE225 seems to act as a multi 
anti-angiogenic drug, modulating both secreted factors and receptors involved in angiogenesis, mouse 
serum levels of circulating VEGF-A were decremented upon NVP-LDE225 administration. In 
addition, the treatment induced an overproduction of THBS1 from tumor cells and of sVEGFR2 from 
both tumor (h-sVEGFR2) and endothelial (m-sVEGFR2) cells, events associated with discouraged 
neovascularization and metastatic potential inhibition (Albuquerque et al., 2009; Henkin and Volpert, 
2011). VEGFR2 levels on tumor surface were deeply reduced as well as some proliferation markers 
such as pERK. Collectively, the combination of NVP-LDE225 and paclitaxel provides a better 
sustained inhibition of both tumor cells proliferation and endothelial cells organization.  
Since PDL1 is frequently overexpressed in TNBC patients and our findings demonstrated an 
activation of Hh pathway in this subset of tumors, we speculate about the potential link beetween 
tumor-immune microenvironment of TNBC and Hh signaling.  
Surprisingly a statistically significant association between PDL1 and GLI1 expression was found in 
TNBC patients TMA. We also evaluated the potential correlation between SMO and PTCH1 
receptors, other members of Hh signaling, and PDL1 interrogating the cBIOportal database. A 
significant overexpression of both receptors was found in PDL1 positive TNBC patients.  
In in vitro experiments we found that PDL1 protein and mRNA levels decreased after 
pharmacological Hh pathway inhibition. Based on these data we hypnotized that Hh activation 
enhanced immune-escape via up-regulation PDL1. In our cellular models we demonstrated a physical 
interaction between GLI1 and the PDL1 promoter; luciferase reporter assay will confirm the 
functional modulation of the PDL1 mediated by GLI1.  
In order to evaluated the effects of Hh inhibition on anti-tumor immune-response we plan to perform 
an in vivo experiment in Balb-C immune-competent mice xenografted with a murine TNBC cell line. 
For this purpose, Hh pathway activation and Hh inhibitors sensitivity were tested in 4T1 TNBC 
murine cells.  In vitro analyses demonstrated that 4T1 cells express GLI1 and that are responsive to 
Hh pathway inhibitors. In 4T1 xenografted Balb-C mice we will evaluate the effects of Hh pathway 
activation on immune features of the tumor microenvironment and the effect of Hh inhibition and 
immunotherapy combined strategy.  
Our data support the clinical development of novel pharmacological combinations that include Hh 
blockade, especially those that could potentiate anti-angiogenic or immunomodulatory effects. Due 
to their ability to target both tumor cells and the pro-tumor microenvironment, Hh inhibitors represent 
promising therapeutics to be clinically investigated in GLI1 overexpressing TNBC patients. 
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